Regulation of TLR2 expression by prostaglandins in brain glia.
TLR have emerged as important primary sensors for diverse stimuli and are increasingly implicated in various diseases. However, the molecular mechanisms underlying the regulation of the TLR system remain poorly understood. In this study, we report that some PGs may control TLR-mediated inflammatory events through modulation of TLR2 expression in brain immune cells. We first found that 15-deoxy-Delta12,14-PG J(2) (15d-PGJ(2)) markedly altered the expression of TLR2 but not TLR4, TLR1, and TLR9 at the message and protein levels in activated glia. Down-regulation of TLR2 expression and downstream events of TLR2 activation, including phagocytosis by 15d-PGJ(2), were also observed in cells treated with representative TLR2 ligands such as lipoteichoic acid and Pam(3)CSK(4). We further revealed that certain 15d-PGJ(2)-related PGs such as 15d-PGD(2) and PGD(2) also suppressed the ligand-stimulated increase of TLR2 expression, whereas PGE(2) and arachidonic acids did not. Interestingly, TLR2 expression was down-regulated even when such PGs were added at several hours after stimulator treatment. These findings appear to be independent of peroxisome proliferator-activated receptor gamma and D prostanoid receptors (DPs) because potent synthetic peroxisome proliferator-activated receptor gamma agonists, selective DP1 agonist, or DP2 agonist did not mimic the effects of such PGs on TLR2 expression. Taken together, our results suggest that 15d-PGJ(2), 15d-PGD(2), and PGD(2) may play notable roles as modulators of the TLR2-mediated inflammatory events, and provide new insight into the resolution of inflammation in the brain.
Yoon
Hee Jung
HJ
Immune and Cell Therapy Branch, National Cancer Center, Goyang, Korea.
Jeon
Sae-Bom
SB
Kim
In-Hoo
IH
Park
Eun Jung
EJ
D000276:Adjuvants, Immunologic / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D000818:Animals; D016718:Arachidonic Acid / Q000502:physiology; D002461:Cell Line, Transformed; D002478:Cells, Cultured; D015232:Dinoprostone / Q000502:physiology; D005786:Gene Expression Regulation / Q000276:immunology; D018836:Inflammation Mediators / Q000502:physiology*; D008024:Ligands; D020935:MAP Kinase Signaling System / Q000276:immunology; D017737:Macrophages, Peritoneal / Q000276:immunology / Q000378:metabolism; D051379:Mice; D008813:Mice, Inbred ICR; D017628:Microglia / Q000276:immunology* / Q000378:metabolism*; D010587:Phagocytosis / Q000276:immunology; D015230:Prostaglandin D2 / Q000031:analogs & derivatives / Q000502:physiology; D011453:Prostaglandins / Q000502:physiology*; D051195:Toll-Like Receptor 2 / Q000819:agonists / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000235:genetics
C477819:15-deoxyprostaglandin J2; D000276:Adjuvants, Immunologic; D018836:Inflammation Mediators; D008024:Ligands; D011453:Prostaglandins; C493486:Tlr2 protein, mouse; D051195:Toll-Like Receptor 2; D016718:Arachidonic Acid; D015232:Dinoprostone; D015230:Prostaglandin D2